
April 8, 2026
Retatrutide is an emerging “triple agonist” therapy targeting GLP-1, GIP, and glucagon receptors, showing strong potential to transform weight loss and metabolic health. Early studies report over 20% weight reduction along with improvements in blood sugar, insulin sensitivity, and appetite control, suggesting benefits beyond the scale.





